John Nagi Kheir

Dr. John Nagi Kheir


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2012 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JKJohn Nagi Kheir
John Nagi Kheir
LSLaurie A. Scharp
Laurie A. Scharp
MBMark A. Borden
Mark A. Borden
ESEdward J. Swanson
Edward J. Swanson
ALAndrew Loxley
Andrew Loxley
FMFrancis X. McGowan
Francis X. McGowan
A foam suspension containing oxygen gas–filled microparticles can deliver life-sustaining oxygen during a 15-min period of complete asphyxia.

8 October 2021 in Critical Care Explorations
Verified
Journal Article
Open access
ACAlexis R. Bs Cole
Alexis R. Bs Cole
FSFrancesca Sperotto
Francesca Sperotto
JDJames A. DiNardo
James A. DiNardo
SCStephanie Carlisle
Stephanie Carlisle
MRMichael J. Rivkin
Michael J. Rivkin
JKJohn Nagi Kheir
John Nagi Kheir
BACKGROUND: Ischemia-reperfusion injury is common in critically ill patients, and directed therapies are lacking. Inhaled hydrogen gas diminishes ischemia-reperfusion injury in models of shock, stroke, and cardiac arrest. The purpose of this study was to investigate the safety of inhaled hydrogen gas at doses required for a clinical efficacy study. DESIGN: Prospective, single-arm study. SETTING: Tertiary care hospital. PATIENTS/SUBJECTS: Eight healthy adult participants. INTERVENTIONS: Subjects underwent hospitalized exposure to 2.4% hydrogen gas in medical air via high-flow nasal cannula (15 L/min) for 24 (n = 2), 48 (n = 2), or 72 (n = 4) hours. MEASUREMENTS AND MAIN RESULTS: Endpoints included vital signs, patient- and nurse-reported signs and symptoms (stratified according to clinical significance), pulmonary function testing, 12-lead electrocardiogram, mini-mental state examinations, neurologic examination, and serologic testing prior to and following exposure. All adverse events were verified by two clinicians external to the study team and an external Data and Safety Monitoring Board. All eight participants (18–30 yr; 50% female; 62% non-Caucasian) completed the study without early termination. No clinically significant adverse events occurred in any patient. Compared with baseline measures, there were no clinically significant changes over time in vital signs, pulmonary function testing results, Mini-Mental State Examination scores, neurologic examination findings, electrocardiogram measurements, or serologic tests for hematologic (except for clinically insignificant increases in hematocrit and platelet counts), renal, hepatic, pancreatic, or cardiac injury associated with hydrogen gas inhalation. CONCLUSIONS: Inhalation of 2.4% hydrogen gas does not appear to cause clinically significant adverse effects in healthy adults. Although these data suggest that inhaled hydrogen gas may be well tolerated, future studies need to be powered to further evaluate safety. These data will be foundational to future interventional studies of inhaled hydrogen gas in injury states, including following cardiac arrest.

1 August 2013 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
JKJohn Nagi Kheir
John Nagi Kheir
BPBrian D. Polizzotti
Brian D. Polizzotti
LTLindsay M. Thomson
Lindsay M. Thomson
DODaniel W. O'COnnell
Daniel W. O'COnnell
KBKatherine J. Black
Katherine J. Black
FMFrancis X. McGowan
Francis X. McGowan

1 September 2017 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
ERErin Rescoe
Erin Rescoe
XTXiaoqi Tang
Xiaoqi Tang
DPDorothy Alison Perry
Dorothy Alison Perry
LSLynn A. Sleeper
Lynn A. Sleeper
JDJames A. DiNardo
James A. DiNardo
JKJohn Nagi Kheir
John Nagi Kheir

20 September 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DPDorothy A. Perry
Dorothy A. Perry
JSJoshua W. Salvin
Joshua W. Salvin
PRPadraic Romfh
Padraic Romfh
PCPeili Chen
Peili Chen
KKKalyani Krishnamurthy
Kalyani Krishnamurthy
JKJohn Nagi Kheir
John Nagi Kheir
Assessing the adequacy of oxygen delivery to tissues is vital, particularly in the fields of intensive care medicine and surgery. As oxygen delivery to a cell becomes deficient, changes in mitochondrial redox state precede changes in cellular function. We describe a technique for the continuous monitoring of the mitochondrial redox state on the epicardial surface using resonance Raman spectroscopy. We quantify the reduced fraction of specific electron transport chain cytochromes, a metric we name the resonance Raman reduced mitochondrial ratio (3RMR). As oxygen deficiency worsens, heme moieties within the electron transport chain become progressively more reduced, leading to an increase in 3RMR. Myocardial 3RMR increased from baseline values of 18.1 ± 5.9 to 44.0 ± 16.9% (P = 0.0039) after inferior vena cava occlusion in rodents (n = 8). To demonstrate the diagnostic power of this measurement, 3RMR was continuously measured in rodents (n = 31) ventilated with 5 to 8% inspired oxygen for 30 min. A 3RMR value exceeding 40% at 10 min predicted subsequent cardiac arrest with 95% sensitivity and 100% specificity [area under the curve (AUC), 0.98], outperforming all current measures, including contractility (AUC, 0.51) and ejection fraction (AUC, 0.39). 3RMR correlated with indices of intracellular redox state and energy production. This technique may permit the real-time identification of critical defects in organ-specific oxygen delivery.

5 May 2016 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
EDElizabeth S. DeWitt
Elizabeth S. DeWitt
KBKatherine J. Black
Katherine J. Black
RTRavi R. Thiagarajan
Ravi R. Thiagarajan
JDJames A. DiNardo
James A. DiNardo
SCSteven D. Colan
Steven D. Colan
JKJohn Nagi Kheir
John Nagi Kheir
Inotropic medications are routinely used to increase cardiac output and arterial blood pressure during critical illness. However, few comparative data exist between these medications, particularly independent of their effects on venous capacitance and systemic vascular resistance. We hypothesized that an isolated working heart model that maintained constant left atrial pressure and aortic blood pressure could identify load-independent differences between inotropic medications. In an isolated heart preparation, the aorta and left atrium of Sprague Dawley rats were cannulated and placed in working mode with fixed left atrial and aortic pressure. Hearts were then exposed to common doses of a catecholamine (dopamine, epinephrine, norepinephrine, or dobutamine), milrinone, or triiodothyronine (n = 10 per dose per combination). Cardiac output, contractility (dP/dtmax), diastolic performance (dP/dtmin and tau), stroke work, heart rate, and myocardial oxygen consumption were compared during each 10-min infusion to an immediately preceding baseline. Of the catecholamines, dobutamine increased cardiac output, contractility, and diastolic performance more than clinically equivalent doses of norepinephrine (second most potent), dopamine, or epinephrine (P < 0.001). The use of triiodothyronine and milrinone was not associated with significant changes in cardiac output, contractility or diastolic function, either alone or added to a baseline catecholamine infusion. Myocardial oxygen consumption was closely related to dP/dtmax (r2 = 0.72), dP/dtmin (r2 = 0.70), and stroke work (r2 = 0.53). In uninjured, isolated working rodent hearts under constant ventricular loading conditions, dobutamine increased contractility and cardiac output more than clinically equivalent doses of norepinephrine, dopamine, and epinephrine; milrinone and triiodothyronine did not have significant effects on contractility.